Mira Pharmaceuticals Inc MIRA

$0.64 +0.01 (1.55%)

Valuation

Market cap: 26,571,000
Revenue TTM: $0
Net income TTM: $-10,440,000
PE ratio: 0.00
Forward PE: —
Profit margin: 0.00%
Debt to equity: 0.00

Trading

Volume: 66,029
Avg volume: 721,822
Day's range: $0.62 – $0.65
Shares out: 42,022,000
Stochastic %K: 5%
Beta: 1.48
Analysts: Strong Sell
Price target: $7.25

Price

Company profile

MIRA Pharmaceuticals, Inc. operates as a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders. The company holds exclusive U.S., Canadian, and Mexican rights for Ketamir-2, a next-generation oral NMDA receptor modulator, that has completed a Phase 1 clinical trial. It also offers oral pharmaceutical marijuana, MIRA-55, is under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia; and SKNY-1, that is in preclinical stage for obesity and nicotine dependence. The company was formerly known as MIRA1a Therapeutics, Inc. MIRA Pharmaceuticals, Inc. was incorporated in 2020 and is based in Miami, Florida.

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 786 432 9792
Website: https://mirapharmaceuticals.com
Address: 1200 Brickell Avenue, Suite 1950 #1183, Miami, United States

Latest news

2026-09-17T12:45:53.000Z · 4 weeks ago

Mira advances Ketamir-2 to chemotherapy-induced peripheral neuropathy

Sep 17, 2026, 8:30 AM EDT · 4 weeks ago

MIRA Pharmaceuticals Advances Ketamir-2 to Phase 2a in Chemotherapy-Induced Peripheral Neuropathy (CIPN) Following FDA Review

2026-09-17T11:50:15.000Z · 4 weeks ago

Mira Pharmaceuticals initiated with a Buy at Maxim

2026-09-01T12:20:37.000Z · 6 weeks ago

Mira Pharmaceuticals announces results from MIRA-55 studies

Sep 1, 2026, 8:00 AM EDT · 6 weeks ago

MIRA Pharmaceuticals Advances Non-Opioid Oral MIRA-55 for Inflammatory Pain Toward IND

2026-08-06T13:38:42.000Z · 2 months ago

Mira reports positive results in 7-day dog study for obesity candidate SKNY-1

Aug 6, 2026, 8:00 AM EDT · 2 months ago

MIRA Reports Positive 7-Day Dog Study Results for SKNY-1

2026-07-30T13:36:37.000Z · 2 months ago

Mira Pharmaceuticals provides update on MIRA-55, SKNY-1

Jul 30, 2026, 8:00 AM EDT · 2 months ago

MIRA Pharmaceuticals Progresses MIRA-55 and SKNY-1 Toward IND-Enabling Studies

2026-07-10T12:11:09.000Z · 3 months ago

Mira Pharmaceuticals reports formulation results for MIRA-55

Jul 10, 2026, 8:00 AM EDT · 3 months ago

MIRA Pharmaceuticals Reports Successful Formulation Results Supporting Development of MIRA-55 as a Non-Opioid Oral Therapy for Chronic Inflammatory Pain

2026-07-06T13:20:06.000Z · 3 months ago

Mira Pharmaceuticals reports SKNY-1 formulation results

Jul 6, 2026, 9:00 AM EDT · 3 months ago

MIRA Pharmaceuticals Reports Successful Formulation Results for SKNY-1, Its Oral Drug Candidate for Obesity and Addiction

2026-06-25T12:20:26.000Z · 3 months ago

Mira Pharmaceuticals reports preclinical pharmacology data on Mira-55

Jun 25, 2026, 8:15 AM EDT · 3 months ago

MIRA Pharmaceuticals Reports New Preclinical Data Demonstrating Mira-55's Differentiated Mechanism of Action and Anxiolytic Activity Relative to THC

2026-06-17T12:22:20.000Z · 4 months ago

Mira Pharmaceuticals submits Phase 2a trial protocol to U.S. FDA for Ketamir-2

Jun 17, 2026, 8:00 AM EDT · 4 months ago

MIRA Pharmaceuticals Submits Phase 2a Clinical Trial Protocol to FDA for Ketamir-2 in Chemotherapy-Induced Peripheral Neuropathy

2026-06-04T12:27:50.000Z · 4 months ago

Mira Pharmaceuticals secures worldwide rights to MIRA-55, SKNY-1

Jun 4, 2026, 8:00 AM EDT · 4 months ago

MIRA Pharmaceuticals Secures Worldwide Exclusive Rights to MIRA-55 and SKNY-1

2026-05-27T14:14:46.000Z · 4 months ago

Mira Pharmaceuticals secures worldwide rights for Ketamir-2

May 27, 2026, 8:00 AM EDT · 4 months ago

MIRA Pharmaceuticals Secures Worldwide Rights for Ketamir-2, Expanding Global IP Portfolio Across 10 Major Markets Ahead of Phase 2a in CIPN

2026-05-26T16:54:44.000Z · 4 months ago

Mira Pharmaceuticals management to meet with Maxim

2026-05-14T16:26:48.000Z · 5 months ago

Mira announces results from Phase 1 trial evaluating Ketamir-2

May 14, 2026, 8:00 AM EDT · 5 months ago

MIRA Pharmaceuticals Reports Positive Unblinded Phase 1 Data for Ketamir-2

2026-05-13T16:28:17.000Z · 5 months ago

Mira announces acceptance of peer-reviewed SKNY-1 manuscript

May 13, 2026, 8:00 AM EDT · 5 months ago

MIRA Pharmaceuticals Announces Acceptance of Peer-Reviewed SKNY-1 Manuscript Highlighting Oral Obesity and Nicotine Addiction Drug Candidate

Mar 23, 2026, 9:00 AM EDT · 7 months ago

MIRA Pharmaceuticals Reports Mira-55 Shows No THC- or Rimonabant-Associated CNS Side Effects in Preclinical Studies

Mar 4, 2026, 8:00 AM EST · 7 months ago

MIRA Pharmaceuticals Completes Phase 1 Dosing of Ketamir-2

Feb 3, 2026, 7:30 AM EST · 8 months ago

MIRA Pharmaceuticals Initiates Final Cohort of Ketamir-2 Phase 1 Clinical Study as Company Prepares for Phase 2a Study

Oct 24, 2025, 7:30 AM EDT · 12 months ago

MIRA Pharmaceuticals Initiates Multiple Ascending Dose (MAD) Phase 1 Study of Oral Ketamir-2 and Selects Chemotherapy-Induced Neuropathic Pain as Lead Phase 2a Indication

Oct 16, 2025, 7:30 AM EDT · 1 year ago

MIRA Pharmaceuticals Announces Oral Mira-55 Outperformed Injected Morphine in Normalizing Pain and Reducing Inflammation, Supporting Its Planned IND for Chronic Inflammatory Pain

Sep 30, 2025, 7:30 AM EDT · 1 year ago

MIRA Pharmaceuticals Closes Acquisition of SKNY Pharmaceuticals, Expands Pipeline with SKNY-1 for Obesity and Nicotine Addiction

Sep 22, 2025, 8:00 AM EDT · 1 year ago

MIRA Pharmaceuticals Announces Favorable Topline Results from Phase 1 SAD Study of Oral Ketamir-2, a Next-Generation Non-Scheduled Ketamine Analog

Sep 16, 2025, 7:30 AM EDT · 1 year ago

MIRA Pharmaceuticals Reports Positive PTSD Data Demonstrating Ketamir-2 Restores Normalized Behavior in Stressed Animals

Sep 12, 2025, 7:30 AM EDT · 1 year ago

MIRA Pharmaceuticals Shareholders Approve Acquisition of SKNY Pharmaceuticals, Advancing Next-Generation Oral Therapeutic for Obesity and Smoking Cessation

Aug 19, 2025, 8:30 AM EDT · 1 year ago

MIRA Pharmaceuticals Announces Completion of Phase 1 Single Ascending Dose for Oral Ketamir-2 with No Safety Concerns, Advances to Multiple Ascending Dose Stage

Aug 12, 2025, 8:30 AM EDT · 1 year ago

MIRA Pharmaceuticals' Second Ketamir-2 Manuscript Accepted for Peer-Reviewed Publication Demonstrating Superior Efficacy in Preclinical Neuropathic Pain Models Versus Ketamine, Gabapentin, or Pregabalin

Jul 30, 2025, 7:30 AM EDT · 1 year ago

MIRA Pharmaceuticals Reports New Topical Ketamir-2 shows comparable effects to Injected Morphine in Preclinical Pain Study

Jul 29, 2025, 7:30 AM EDT · 1 year ago

MIRA Pharmaceuticals Announces FDA Clearance of IND for Ketamir-2, Enabling U.S. Clinical Trials in Neuropathic Pain

Jul 11, 2025, 8:00 AM EDT · 1 year ago

MIRA Reports Clear Reversal of Anxiety-Related Behavior in Animal Model Using SKNY-1, an Oral Drug Candidate for Obesity and Nicotine Addiction Under Definitive Agreement for Acquisition

Jul 3, 2025, 8:00 AM EDT · 1 year ago

MIRA Reports Potent Inflammatory Pain Relief from Non-Psychoactive Marijuana Analog Mira-55 in Animal Model, Matching Morphine Without Opioid Risks

Jun 30, 2025, 8:00 AM EDT · 1 year ago

MIRA Reports Up to 30% Weight Loss and Reversal of High-Calorie and Nicotine Cravings in an Animal Model of Obesity and Craving Using SKNY-1, a Drug Candidate Under Definitive Agreement for Acquisition

Jun 25, 2025, 8:00 AM EDT · 1 year ago

MIRA Pharmaceuticals Announces New Data Underscoring Potential of SKNY-1 - A Drug Candidate Pending Acquisition - To Disrupt Weight Loss and Smoking Cessation Markets Without CNS Side Effects

Jun 18, 2025, 8:30 AM EDT · 1 year ago

MIRA Pharmaceuticals' Lead Drug Candidate Ketamir-2 First Manuscript Accepted for Publication in the Peer-Reviewed Journal Frontiers in Pharmacology

May 28, 2025, 8:30 AM EDT · 1 year ago

MIRA Pharmaceuticals to Participate in BIO 2025 in Boston and Highlights Ongoing Progress Across Clinical Program

May 8, 2025, 8:00 AM EDT · 1 year ago

MIRA Pharmaceuticals Announces Board Approval of SKNY Acquisition Reflecting $60+ Million in Combined Enterprise Value Based on Independent Review

May 6, 2025, 8:00 AM EDT · 1 year ago

MIRA Pharmaceuticals Reports No Brain Toxicity in FDA-Required Study of Ketamir-2, Confirming Absence of Ketamine-Linked Neurotoxicity

Apr 23, 2025, 8:00 AM EDT · 1 year ago

MIRA Pharmaceuticals Reports Positive In Vitro Drug Release Data for Topical Ketamir-2, Targeting $11B+ U.S. Topical Pain Relief Market and Exploring FDA Fast Track Designation

Apr 16, 2025, 8:00 AM EDT · 1 year ago

MIRA Pharmaceuticals Announces Positive Results for Ketamir-2 in Diabetic Neuropathy Animal Model, Reinforcing Confidence Ahead of Phase I Completion

Apr 1, 2025, 8:00 AM EDT · 1 year ago

MIRA Pharmaceuticals Enrolls First Subjects in Phase 1 Clinical Trial of Ketamir-2 for Neuropathic Pain

Mar 24, 2025, 7:30 AM EDT · 1 year ago

MIRA Pharmaceuticals Signs Binding Letter of Intent to Acquire SKNY Pharmaceuticals, Securing a $5 Million Capital Infusion to Advance Weight Loss and Smoking Cessation Drug Development

Mar 13, 2025, 8:00 AM EDT · 1 year ago

MIRA Pharmaceuticals Expands Ketamir-2 Development with Topical Treatment for Localized Neuropathic and Inflammatory Pain

Mar 4, 2025, 8:00 AM EST · 1 year ago

MIRA Pharmaceuticals Announces Approval and Initiation of Phase 1 Clinical Trial for Ketamir-2 in Neuropathic Pain

Dec 19, 2024, 9:00 AM EST · 1 year ago

MIRA Pharmaceuticals Submits IND for Ketamir-2 to FDA, Marking a Significant Milestone in the Company's Pipeline Development

Dec 10, 2024, 8:30 AM EST · 1 year ago

MIRA Pharmaceuticals Validates Ketamir-2's Safety Profile With No Adverse Findings, Paving the Way for IND Submission by Year-End

Nov 20, 2024, 7:44 AM EST · 1 year ago

MIRA Reveals Innovative Phase I/IIa Protocol Design and Selection of Clinical Trial Site

Oct 28, 2024, 7:30 AM EDT · 1 year ago

MIRA Pharmaceuticals' Ketamir-2 Shows 60% Greater Efficacy Than FDA-Approved Gabapentin in Reversing Chemotherapy-Induced Neuropathic Pain

Oct 21, 2024, 7:30 AM EDT · 1 year ago

MIRA Pharmaceuticals Announces Ketamir-2 Outperforms Current FDA-Approved Neuropathic Pain Treatments, Gabapentin and Pregabalin, in Preclinical Study

Sep 27, 2024, 7:30 AM EDT · 2 years ago

MIRA Pharmaceuticals Announces New Preclinical Data for Ketamir-2 to Be Presented at the 18th Annual Pain Therapeutics Summit in Boston on October 28-29, 2024

Sep 18, 2024, 7:00 AM EDT · 2 years ago

MIRA Pharmaceuticals Advances Ketamir-2 Development Following Phase 1 Design Completion, Focusing on Early Clinical Efficacy Demonstration for Neuropathic Pain in 2025

Sep 11, 2024, 7:30 AM EDT · 2 years ago

MIRA Pharmaceuticals Designates Neuropathic Pain as Primary Indication for Ketamir-2 and Submits Pre-IND Meeting Request to FDA

Aug 26, 2024, 8:00 AM EDT · 2 years ago

MIRA Pharmaceuticals Achieves 100% Reversal of Neuropathic Pain With Oral Ketamir-2 in Breakthrough Study

Aug 19, 2024, 7:30 AM EDT · 2 years ago

MIRA Pharmaceuticals Showcases Significant Progress and Announces Final Phase of Regulatory Work as It Prepares for IND Submission by Year-End

Aug 12, 2024, 8:00 AM EDT · 2 years ago

MIRA Pharmaceuticals Unveils Ketamir-2's Principal Metabolite: Nor-Ketamir - a Longer-Acting, Brain Penetrating and Selective Compound Acting on the NMDA PCP Receptor

Stocktwits

227z_Acacias Oct 16, 4:47 PM

huge candidate and victory is this can be bought by larger company $MIRA neuropathic pain and ptsd / anxiety orders as well can be helped with ketmir-2 and Mira-55 analogue derivatives from ketamine and marijuana non toxic compare to peers

0 replies

227z_Acacias Oct 16, 4:43 PM

$MIRA down and beat but sure to rise some day testing for these candidates come around a couple times a year

0 replies

227z_Acacias Oct 8, 7:37 AM

$MIRA Pharmaceuticals Targets Q1 2027 IND Filing | MIRA Stock News https://www.stocktitan.net/news/MIRA/mira-pharmaceuticals-advances-non-opioid-oral-mira-55-for-jx60i6hmo73z.html

0 replies